Sir,
We read with great interest the article by Almansa et al. published in Digestive and Liver Disease regarding the role of Doppler endoscopic ultrasound as a comprehensive test to evaluate patients with chronic upper abdominal pain in order to exclude chronic mesenteric ischaemia [1] . In this study, authors employed, both in Doppler endoscopic ultrasound and Dopper transabdominal ultrasound, measurement of Peak Systolic Velocity (PSV) in celiac artery and superior mesenteric artery as single parameter for the detection of chronic mesenteric ischaemia. We would add that, beside PSV, another Doppler parameter could be considered: EndDiastolic Velocity (EDV) appears comparable or superior to PSV in identify significant arteriography-detected stenosis, and is not influenced by an hyperdynamic circulation as for PSV [2] [3] [4] [5] . In the study of Almansa et al., Doppler endoscopic ultrasound (assessed by means of PSV) presented a specificity of 84% in detecting chronic mesenteric ischaemia; this figure could be even more appealing employing EDV.
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None declared. Nationwide prediction of future expenditure for protease inhibitors in chronic hepatitis C Dear Editor, Peginterferon plus ribavirin is the current standard of care for chronic hepatitis C, which determines sustained virological response (SVR) in 30-50% of patients. Protease inhibitors (namely boceprevir and telaprevir) are a further advancement that could increase SVR to approximately 60% [1] . Boceprevir and telaprevir have already been approved by the Food and Drug Administration (FDA) and are about to be marketed in Europe (boceprevir is available in France where its cost per patient is around D 22,000 according to the website http://viralmatters.blogspot.com). The globalization of pharmaceutical markets has much increased the international homogeneity of drug prices; hence, transferring the cost of innovative drugs from one country to another is likely to imply a reasonable approximation.
Reference
Predicting the economic impact of adding a protease inhibitor to patients treated for hepatitis C is a crucial point in terms of pharmaceutical governance, especially in countries like Italy where the national health system provides full economic coverage of all essential treatments. The first step in evaluating an innovative treatment is to determine its cost-effectiveness; if the pharmacoeconomic profile is acceptable and the drug is therefore likely to be used, the next step is to estimate the budget impact.
Since preliminary studies [2] indicate that the cost-effectiveness of these protease inhibitors is favourable, a budget impact analysis focused on these agents is worthwhile. The national expenditure for ribavirin in Italy has been D 33 million in 2009; assuming that each patient receives 840 capsules for a whole treatment (considering a cost of D 4.2 per capsule, and including adjustments for treatment interruptions and suboptimal compliance [3] ), this figure of national expenditure indicates that 9300 Italian patients/year receive treatment for hepatitis C regardless of their genotype. Given that genotype 1 accounts for 60% of all patients [4] , this translates into a prediction of 5500 Italian patients with genotype 1 to be treated yearly with a protease inhibitor.
To estimate the economic impact of adding a protease inhibitor to these patients, we used a prediction model described previously [5] . According to this model, the yearly expenditure for the drug is directly proportional to the yearly number of treated patients (where the proportionality factor is the yearly cost per patient). The model is not drug-specific because the mathematical function simply handles an initial phase where expenditure increases as more and more patients of the eligible yearly population are being treated over time. Fig. 1 shows the results of our budget impact analysis for protease inhibitors based on this model. In our base-case prediction, after projecting the expenditure for up to 5500 patients/year from mid-2012 until 2017, the overall budget impact is estimated to be D 115 million per year at steady state (solid line).
Two factors affect the above budget impact analysis by acting in opposite directions. The first is that the patients actually receiving
Abstract
The combination of either boceprevir or telaprevir with ribavirin and interferon (triple therapy) has been shown to be more effective than ribavirin+interferon (dual therapy) for the treatment of genotype 1 hepatitis C. Since the benefit of these treatments takes place after years, simulation models are needed to predict long-term outcomes. In simulation models, the choice of different values of yearly discount rates (e.g., 6%, 3.5%, 2%, 1.5% or 0%) influences the results, but no studies have specifically addressed this issue. We examined this point by determining the long-term benefits under different conditions on the basis of standard modelling and using quality-adjusted life years (QALYs) to quantify the benefits. In our base case scenario, we compared the long-term benefit between patients given a treatment with a 40% sustained virologic response (SVR) (dual therapy) and patients given a treatment with a 70% SVR (triple therapy), and we then examined how these specific yearly discount rates influenced the incremental benefit. The gain between a 70% SVR and a 40% SVR decreased from 0.45 QALYs with a 0% discount rate to 0.22 QALYs with a 6% discount rate (ratio between the two values = 2.04).
Testing the other discounting assumptions confirmed that the discount rate has a marked impact on the magnitude of the model-estimated incremental benefit. In conclusion, the results of our analysis can be helpful to better interpret cost-effectiveness studies evaluating new treatment for hepatitis C.
TO THE EDITOR
The review by Tsubota et al [1] has examined the main options available for the treatment of hepatitis C, including two antiviral drugs that have recently been marketed in many countries. Focusing more thoroughly on these two innovative agents is worthwhile because boceprevir and telaprevir, along with other innovative agents, are thought to be an important advancement in the treatment of this disease [2] , although at a high cost.
Hepatitis C virus (HCV) genotype 1, which accounts for 60% of all HCV-infected patients [3] [4] [5] , is the target at which these two new agents are directed in combination with ribavirin + interferon. Considering that the combination of either boceprevor or telaprevir with ribavirin+interferon (triple therapy) has been shown T he estimated global prevalence of hepatitis C virus (HCV) infection is 2.2%, corresponding to about 130 million HCV-positive persons worldwide, most of whom are chronically infected.
1 A recent revision 2 reported that the estimated prevalence of HCV infection in Europe ranges from 0.6% to 5.6%. This is of increasing interest because HCV is a leading cause of both cirrhosis and hepatocellular carcinoma (HCC) in Western countries. The prevalence of HCV-related cirrhosis and its complications will continue to increase through the next decade, and will mostly affect those above age 60.
3
Considering the burden of HCV-related cirrhosis and its complications, the achievement of a sustained virologic response (SVR) is a very important surrogate outcome in the management of chronic hepatitis C (CHC) patients. In fact, viral eradication prevents the development of cirrhosis 4 and its complications, such as esophageal varices 5 and HCC, 6 and leads to a decrease in liver-related death. Randomized controlled trials (RCTs) show that triple therapy (TT) with peginterferon alpha, ribavirin, and boceprevir (BOC) or telaprevir (TVR) is more effective than peginterferon-ribavirin dual therapy (DT) in the treatment of previously untreated patients with genotype 1 (G1) chronic hepatitis C (CHC). We assessed the cost-effectiveness of TT compared to DT in the treatment of untreated patients with G1 CHC. We created a Markov Decision Model to evaluate, in untreated Caucasian patients age 50 years, weight 70 kg, with G1 CHC and Metavir F2 liver fibrosis score, for a time horizon of 20 years, the cost-effectiveness of the following five competing strategies: 1) boceprevir response-guided therapy (BOC-RGT); 2) boceprevir IL28B genotype-guided strategy (BOC-IL28B); 3) boceprevir rapid virologic response (RVR)-guided strategy (BOC-RVR); 4) telaprevir response-guided therapy (TVR-RGT); 5) telaprevir IL28B genotype-guided strategy (TVR-IL28B). Outcomes included life-years gained (LYG), costs (in 2011 euros) and incremental cost-effectiveness ratio (ICER). In the base-case analysis BOC-RVR and TVR-IL28B strategies were the most effective and cost-effective of evaluated strategies. LYG was 4.04 with BOC-RVR and 4.42 with TVR-IL28B. ICER compared with DT was €8.304 per LYG for BOC-RVR and €11.455 per LYG for TVR-IL28B. The model was highly sensitive to IL28B CC genotype, likelihood of RVR and sustained virologic response, and BOC/TVR prices. Conclusion: In untreated G1 CHC patients age 50 years, TT with first-generation protease inhibitors is costeffective compared with DT. Multiple strategies to reduce costs and improve effectiveness include RVR or genotype-guided treatment. (HEPATOLOGY 2012; 56:850-860) T he estimated global prevalence of hepatitis C virus (HCV) infection is 2.2%, corresponding to about 130 million HCV-positive persons worldwide, most of whom are chronically infected.
Considering the burden of HCV-related cirrhosis and its complications, the achievement of a sustained virologic response (SVR) is a very important surrogate outcome in the management of chronic hepatitis C (CHC) patients. In fact, viral eradication prevents the development of cirrhosis 4 and its complications, such as esophageal varices 5 and HCC, 6 and leads to a decrease in liver-related death.
Introduction
Approximately 50% of all patients with genotype 1 chronic hepatitis C (G1 CHC) treated with dual therapy (DT) with peginterferon (PegIFN) plus ribavirin (RBV) experience treatment failure [1] . This means they represent a growing cohort of individuals at higher risk of liver-related complications [2] . Considering the high likelihood of disease progression of CHC patients failing DT [3, 4] , and the burden of hepatitis C virus (HCV)-related cirrhosis and its related complications, the achievement of a sustained virological response (SVR) is a very important surrogate outcome in patient management. In fact, viral eradication prevents the development of cirrhosis [5] and its related complications, such as oesophageal varices [6] and hepatocellular carcinoma (HCC) [7] , and reduces liver-related death [8] .
Two large randomized controlled trials (RCTs) [3, 4] , studying long-term maintenance therapy with low-dose PegIFN in CHC patients failing DT, showed no benefit in terms of progression of liver disease. Several RCTs [9, 10] and a recent meta-analysis [11] showed that re-treatment of G1 non-responders with DT favours SVR achievement in only 15% of patients. Guidelines of the European Association for the Study of the Liver (EASL) [12] and of the American Association for the Study of Liver Disease (AASLD, 2011) [13] recommended that patients infected with G1 HCV and who failed to eradicate HCV after prior DT should not be re-treated with the same drug regimen. It was suggested 
Background:
The progression of hepatitis C virus (HCV) disease usually occurs over a 10-year period. HCV-related complications as well as the highly debilitating effects on patients represent a significant item of expenditure for the National Health Service. Early detection of HCV infection is an excellent opportunity to improve patients' quality of life and to rationalize resource allocation. Objective: The aim of this study was to provide a cost-effectiveness evaluation of an anti-HCV screening program in the Italian National Health Service perspective. Methods: We built a Markov model made up of two arms. The ''Test Strategy'' arm involves a screening program based on the enzyme immunoassay for detection of antibodies as first-level test and the research of HCV RNA as second-level detection; patients with positive test results are treated with peg-interferon alfa in combination with ribavirine. Parameters were derived from the literature and validated through experts' opinion. Costs and benefits were discounted by 3.5%. Results were expressed as cost/qualityadjusted life-year (QALY) gained through the screening program compared with the treatment of symptomatic patients. Deterministic and probabilistic sensitivity analysis was performed. Results: The incremental cost-effectiveness ratio of the ''Test Strategy'' is €5171/QALY, definitively below the cost/QALY of other approved treatments in Italy. Model results turned out as sensitive to the age of the target population, the prevalence of HCV infection, and the time horizon adopted. ConcluIntroduction Viral hepatitis is a chronic condition with a latent, nonlinear disease progression. Hepatitis C virus (HCV) disease can remain asymptomatic for decades and resolves spontaneously only in exceptional cases. The disease normally takes over a decade to progress, although this may be accelerated by the presence of various cofactors including alcohol use, diabetes mellitus (for which HCV is a risk factor), the age at which the disease was developed, and coinfection with HIV or other hepatotropic viruses. Between 10% and 40% of patients with chronic HCV infection will develop cirrhosis, depending on the occurrence of these cofactors. The annual incidence of death due to cirrhosis complications is around 4%, while the annual incidence of hepatocarcinoma (HCC) among patients with chronic HCV infection is 1% to 5%. Patients with HCC have a 33% chance of surviving beyond 1 year after its onset [1] .
Early diagnosis following a screening test for chronic hepatitis is an effective tool for the prompt treatment of HCV infection, stopping the progression of any liver disease. Numerous studies have been conducted in recent years to investigate the costeffectiveness ratio of screening for viral hepatitis. Many of these studies have used decisional models because these tools are wellsuited to the design of early diagnosis programs, which usually require considerable investment in the present but pay back their benefits to health many years later. A recent systematic review [2] summarized the results of seven studies about hepatitis C screening programs carried out in France, Great Britain, and the United Kingdom on subgroups of patients. The incremental costeffectiveness ratio (ICER) of screening compared with treatment of symptomatic patients was found to range between €3,900 and €243,700 per life-year gained, or €18,000 and €1,151,000 per quality-adjusted life-year (QALY) gained. The authors concluded that screening was cost-effective in populations with a high prevalence of HCV infection but excessively costly in populations with a low prevalence.
The purpose of this study was to evaluate the costeffectiveness of a screening strategy aimed at identifying HCVpositive patients in comparison with the treatment of patients who have developed cirrhosis or HCC following undiagnosed chronic hepatitis.
Methods

Model Structure
We studied HCV disease progression up to death, simulating the observation of a cohort of 100,000 individuals from the general 
